Delcath Systems (DCTH) Projected to Post Quarterly Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $14.96 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Delcath Systems Price Performance

Shares of Delcath Systems stock opened at $14.66 on Thursday. The stock has a market capitalization of $468.74 million, a price-to-earnings ratio of -10.86 and a beta of 0.86. The business has a 50-day moving average of $14.13 and a 200 day moving average of $11.40. Delcath Systems has a 12 month low of $3.70 and a 12 month high of $16.97.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Delcath Systems in a research note on Tuesday, January 14th. Craig Hallum lifted their price objective on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.25.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.